Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of BioAtla Inc (NASDAQ: BCAB) was $2.01 for the day, down -3.83% from the previous closing price of $2.09. In other words, the price has decreased by -$3.83 from its previous closing price. On the day, 0.55 million shares were traded. BCAB stock price reached its highest trading level at $2.1273 during the session, while it also had its lowest trading level at $1.985.
Ratios:
Our analysis of BCAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.81 and its Current Ratio is at 3.81. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on September 15, 2022, initiated with a Mkt Outperform rating and assigned the stock a target price of $17.
On May 05, 2022, Credit Suisse Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $35 to $5.
On March 21, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on March 21, 2022, with a $25 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 26 ’23 when MCBRINN SYLVIA bought 4,000 shares for $2.33 per share. The transaction valued at 9,320 led to the insider holds 15,125 shares of the business.
SHORT JAY M PHD bought 50,000 shares of BCAB for $106,910 on Dec 20 ’23. The Chief Executive Officer now owns 1,439,283 shares after completing the transaction at $2.14 per share. On Dec 19 ’23, another insider, STEINMAN LAWRENCE, who serves as the Director of the company, bought 20,000 shares for $2.05 each. As a result, the insider paid 41,048 and bolstered with 38,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAB now has a Market Capitalization of 100770944 and an Enterprise Value of 37154832.
Stock Price History:
Over the past 52 weeks, BCAB has reached a high of $4.02, while it has fallen to a 52-week low of $1.14. The 50-Day Moving Average of the stock is 7.91%, while the 200-Day Moving Average is calculated to be -6.17%.
Shares Statistics:
BCAB traded an average of 1.18M shares per day over the past three months and 755300 shares per day over the past ten days. A total of 48.08M shares are outstanding, with a floating share count of 39.01M. Insiders hold about 19.30% of the company’s shares, while institutions hold 40.47% stake in the company. Shares short for BCAB as of 1728950400 were 5242717 with a Short Ratio of 4.43, compared to 1726185600 on 4450925. Therefore, it implies a Short% of Shares Outstanding of 5242717 and a Short% of Float of 12.1300004.
